• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Takeuchi Shinji  竹内 伸司

ORCIDConnect your ORCID iD *help
… Alternative Names

TAKEUCHI SHINJI  竹内 伸司

TAKEUCHI Shinji  竹内 伸司

Less
Researcher Number 90565384
Other IDs
External Links
Affiliation (Current) 2025: 金沢大学, 附属病院, 講師
Affiliation (based on the past Project Information) *help 2017 – 2023: 金沢大学, 附属病院, 講師
2015: 金沢大学, がん進展制御研究所・腫瘍内科, 助教
2011 – 2014: 金沢大学, がん進展制御研究所, 助教
Review Section/Research Field
Principal Investigator
Respiratory organ internal medicine / Basic Section 53030:Respiratory medicine-related
Except Principal Investigator
Respiratory organ internal medicine / Basic Section 50020:Tumor diagnostics and therapeutics-related
Keywords
Principal Investigator
アポトーシス / HDAC阻害薬 / EGFR変異肺がん / BIM遺伝子多型 / EGFR変異 / 肺癌 / 肺がん / ALK融合遺伝子 / STAT3 / ALK肺がん … More / トランスレーショナルリサーチ / 癌 / HDAC3 / Osimertinib / 非小細胞肺癌 / apoptosis / EGFR-TKI / BIM / 活性酸素 / ROS / Ras … More
Except Principal Investigator
EMT / 薬剤耐性 / miR-200 / ALK融合遺伝子陽性肺癌 / HDAC阻害薬 / ALK / 耐性 / osimertinib / miR200c / GSK-3 / オシメルチニブ / 肺がん / EGFR / 第3世代-TKI / EGFR変異肺癌 / AXL / EGFR肺癌 / ゲフィチニブ / 上皮成長因子受容体 / 線維芽細胞 / MET / 肝細胞増殖因子 / 公子標的治療 / PI3K / バイオマーカー / EGFR遺伝子変異 / Met / HGF / EGFR-TKI / 肺癌 Less
  • Research Projects

    (7 results)
  • Research Products

    (62 results)
  • Co-Researchers

    (9 People)
  •  Development of Novel Therapies Targeting Apoptosis Resistance Factors in ALK-rearranged Lung CancerPrincipal Investigator

    • Principal Investigator
      Takeuchi Shinji
    • Project Period (FY)
      2020 – 2023
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Review Section
      Basic Section 53030:Respiratory medicine-related
    • Research Institution
      Kanazawa University
  •  Development of treatment to overcome TKI resistance caused by EMT in lung cancer

    • Principal Investigator
      Fukuda Koji
    • Project Period (FY)
      2018 – 2020
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Review Section
      Basic Section 50020:Tumor diagnostics and therapeutics-related
    • Research Institution
      Kanazawa University
  •  Development of therapy for overcoming resistance to mutant selective EGFR-TKI due to persistance of apoptosisPrincipal Investigator

    • Principal Investigator
      TAKEUCHI SHINJI
    • Project Period (FY)
      2017 – 2020
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Research Field
      Respiratory organ internal medicine
    • Research Institution
      Kanazawa University
  •  Development of therapies for overcoming EMT-associated irreversible tyrosine kinase inhibitor resistance in EGFR lung cancer

    • Principal Investigator
      Fukuda Koji
    • Project Period (FY)
      2014 – 2015
    • Research Category
      Grant-in-Aid for Young Scientists (B)
    • Research Field
      Respiratory organ internal medicine
    • Research Institution
      Kanazawa University
  •  Development of therapy for circumvention of EGFR-TKI resistance due to BIM polymorphism in EGFR mutant lung cancer.Principal Investigator

    • Principal Investigator
      TAKEUCHI Shinji
    • Project Period (FY)
      2013 – 2014
    • Research Category
      Grant-in-Aid for Young Scientists (B)
    • Research Field
      Respiratory organ internal medicine
    • Research Institution
      Kanazawa University
  •  Development of novel targeted therapy for lung cancer with activating Ras mutationPrincipal Investigator

    • Principal Investigator
      TAKEUCHI Shinji
    • Project Period (FY)
      2011 – 2012
    • Research Category
      Grant-in-Aid for Young Scientists (B)
    • Research Field
      Respiratory organ internal medicine
    • Research Institution
      Kanazawa University
  •  Development of individual therapy for overcoming HGF-induced molecular targeted drug-resistance in EGFR-mutant lung cancer

    • Principal Investigator
      YANO Seiji
    • Project Period (FY)
      2009 – 2011
    • Research Category
      Grant-in-Aid for Scientific Research (B)
    • Research Field
      Respiratory organ internal medicine
    • Research Institution
      Kanazawa University

All 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Other

All Journal Article Presentation Book Other

  • [Book] 分子呼吸器病2014

    • Author(s)
      竹内伸司、矢野聖二
    • Publisher
      先端医学社
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Book] Biotherapy 25巻5号2011

    • Author(s)
      竹内伸司, 矢野聖二
    • Publisher
      がんと化学療法社
    • Data Source
      KAKENHI-PROJECT-23790903
  • [Journal Article] STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.2022

    • Author(s)
      Yanagimura N, Takeuchi S, Fukuda K, Arai S, Tanimoto A, Nishiyama A, Ogo N, Takahashi H, Asai A, Watanabe S, Kikuchi T, Yano S.
    • Journal Title

      NPJ Precis Oncol

      Volume: 6 Issue: 1 Pages: 11-11

    • DOI

      10.1038/s41698-022-00254-y

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-18KT0019, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-21H02609, KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-23K20323
  • [Journal Article] Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)2021

    • Author(s)
      Takeuchi Shinji、Yanagitani Noriko、Seto Takashi、Hattori Yoshihiro、Ohashi Kadoaki、Morise Masahiro、Matsumoto Shingo、Yoh Kiyotaka、Goto Koichi、Nishio Makoto、Takahara Shizuko、Kawakami Takahiro、Imai Yasuhito、Yoshimura Kenichi、Tanimoto Azusa、Nishiyama Akihiro、Murayama Toshinori、Yano Seiji
    • Journal Title

      Translational Lung Cancer Research

      Volume: 10 Issue: 1 Pages: 314-325

    • DOI

      10.21037/tlcr-20-549

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19K08625, KAKENHI-PROJECT-19K07910
  • [Journal Article] Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.2020

    • Author(s)
      Shinji Takeuchi, Tetsunari Hase, et al.
    • Journal Title

      Cancer science

      Volume: 111 Issue: 2 Pages: 561-570

    • DOI

      10.1111/cas.14260

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K07443
  • [Journal Article] MET amplification results in heterogeneous responses to osimertinib in EGFR ‐mutant lung cancer treated with erlotinib2020

    • Author(s)
      Nishiyama Akihiro、Takeuchi Shinji、Adachi Yuta、Otani Sakiko、Tanimoto Azusa、Sasaki Motoko、Matsumoto Shingo、Goto Koichi、Yano Seiji
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 10 Pages: 3813-3823

    • DOI

      10.1111/cas.14593

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K06985
  • [Journal Article] Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with <i>BIM</i> deletion polymorphism2020

    • Author(s)
      Arai S, Yano S, et al.
    • Journal Title

      J. Med. Invest.

      Volume: 67 Issue: 3.4 Pages: 343-350

    • DOI

      10.2152/jmi.67.343

    • NAID

      130007936892

    • ISSN
      1343-1420, 1349-6867
    • Language
      English
    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-17K09649
  • [Journal Article] Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR ‐mutant lung cancer2020

    • Author(s)
      Fukuda Koji、Takeuchi Shinji、Arai Sachiko、Kita Kenji、Tanimoto Azusa、Nishiyama Akihiro、Yano Seiji
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 7 Pages: 2374-2384

    • DOI

      10.1111/cas.14454

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K07261
  • [Journal Article] Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression2020

    • Author(s)
      Tanimoto Azusa、Matsumoto Shingo、Takeuchi Shinji、Arai Sachiko、Fukuda Koji、Nishiyama Akihiro、Yoh Kiyotaka、Ikeda Takaya、Furuya Naoki、Nishino Kazumi、Ohe Yuichiro、Goto Koichi、Yano Seiji
    • Journal Title

      Clinical Cancer Research

      Volume: 27 Issue: 5 Pages: 1410-1420

    • DOI

      10.1158/1078-0432.ccr-20-2853

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K15922
  • [Journal Article] GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer2020

    • Author(s)
      Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Kenji Kita, Azusa Tanimoto, Akihiro Nishiyama, Seiji Yano
    • Journal Title

      Cancer Science

      Volume: -

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-18K07261
  • [Journal Article] Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.2020

    • Author(s)
      Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-Mei Zheng, Yi-Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, Seiji Yano
    • Journal Title

      Journal of thoracic oncology

      Volume: 15 Issue: 5 Pages: 752-765

    • DOI

      10.1016/j.jtho.2020.01.001

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19K16738, KAKENHI-PROJECT-19H03524
  • [Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.2019

    • Author(s)
      Fukuda K, Takeuchi S,Yano S, et al.
    • Journal Title

      Cancer Res

      Volume: 79(7) Issue: 7 Pages: 1658-1670

    • DOI

      10.1158/0008-5472.can-18-2052

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19K07346, KAKENHI-PROJECT-19H03665
  • [Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status2019

    • Author(s)
      Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, et al
    • Journal Title

      Cancer Reseach

      Volume: 79 Pages: 1658-1670

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-18K07261
  • [Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.2019

    • Author(s)
      Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.
    • Journal Title

      Cancer Resarch

      Volume: 79 Pages: 1658-1670

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-18K07261
  • [Journal Article] Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.2018

    • Author(s)
      Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP.
    • Journal Title

      Nat Commun.

      Volume: 9 Issue: 1 Pages: 3198-3198

    • DOI

      10.1038/s41467-018-05626-2

    • NAID

      120006949473

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K09649
  • [Journal Article] Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.2018

    • Author(s)
      Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.
    • Journal Title

      Nat Commun.

      Volume: 10 Issue: 1 Pages: 259-259

    • DOI

      10.1038/s41467-018-08074-0

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-18KT0019, KAKENHI-PROJECT-19K08608, KAKENHI-PROJECT-19H03665
  • [Journal Article] Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.2017

    • Author(s)
      Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, Ong ST, Yano S.
    • Journal Title

      Clin Cancer Res.

      Volume: 23 Issue: 12 Pages: 3139-3149

    • DOI

      10.1158/1078-0432.ccr-16-2271

    • Peer Reviewed / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K09649
  • [Journal Article] Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.2017

    • Author(s)
      Taniguchi H, Yamada T, Takeuchi S, Arai S, Fukuda K, Sakamoto S, Kawada M, Yamaguchi H, Mukae H, Yano S.
    • Journal Title

      Cancer Sci.

      Volume: 108 Issue: 7 Pages: 1378-1385

    • DOI

      10.1111/cas.13268

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-15K06888
  • [Journal Article] Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.2017

    • Author(s)
      Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii G, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S.
    • Journal Title

      Cancer Sci.

      Volume: 108 Issue: 4 Pages: 696-703

    • DOI

      10.1111/cas.13190

    • NAID

      120006306235

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308
  • [Journal Article] In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.2017

    • Author(s)
      Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S.
    • Journal Title

      Cancer Med

      Volume: 6 Issue: 12 Pages: 2972-2983

    • DOI

      10.1002/cam4.1255

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-26461700, KAKENHI-PROJECT-15K13100
  • [Journal Article] Phase I study of combined therapy with vorinostat and gefitinib to treat <i>BIM</i> deletion polymorphism-associated resistance in <i>EGFR</i>-mutant lung cancer (VICTROY-J): a study protocol2017

    • Author(s)
      Takeuchi S, Yoshimura K, Fujiwara T, Ando M, Shimizu S, Nagase K, Hasegawa Y, Takahashi T, Katakami N, Inoue A, Yano S.
    • Journal Title

      J. Med. Invest.

      Volume: 64 Issue: 3.4 Pages: 321-325

    • DOI

      10.2152/jmi.64.321

    • NAID

      130006105349

    • ISSN
      1343-1420, 1349-6867
    • Language
      English
    • Data Source
      KAKENHI-PROJECT-17K09649
  • [Journal Article] In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.2015

    • Author(s)
      Nanjo S, Yano S, et al.
    • Journal Title

      Cancer Sci

      Volume: 106 Issue: 3 Pages: 244-52

    • DOI

      10.1111/cas.12600

    • NAID

      120005830611

    • Peer Reviewed / Acknowledgement Compliant / Open Access
    • Data Source
      KAKENHI-PLANNED-22112010, KAKENHI-PLANNED-23112101, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24650625, KAKENHI-PROJECT-24659403, KAKENHI-PROJECT-25860640, KAKENHI-PROJECT-26250028, KAKENHI-PROJECT-26293322, KAKENHI-PROJECT-25462190, KAKENHI-PROJECT-25462202
  • [Journal Article] Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance.2014

    • Author(s)
      Takeuchi S, Yano S.
    • Journal Title

      Respir Investig

      Volume: 52 Issue: 6 Pages: 348-56

    • DOI

      10.1016/j.resinv.2014.10.002

    • Peer Reviewed / Acknowledgement Compliant / Open Access
    • Data Source
      KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-25860640
  • [Journal Article] Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.2014

    • Author(s)
      Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S.
    • Journal Title

      Oncotarget

      Volume: 5 Pages: 4920-4928

    • NAID

      120005830567

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Journal Article] Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.2013

    • Author(s)
      Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S.
    • Journal Title

      PLoS One

      Volume: 8

    • NAID

      120005368227

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Journal Article] EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.2013

    • Author(s)
      Nakagawa T, Yano S, et al.
    • Journal Title

      Cancer Res

      Volume: 73 Issue: 8 Pages: 2428-34

    • DOI

      10.1158/0008-5472.can-12-3479

    • Peer Reviewed
    • Data Source
      KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-25860638, KAKENHI-PROJECT-25860640, KAKENHI-ORGANIZER-22112001
  • [Journal Article] The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.2013

    • Author(s)
      Sano T, Yano S, et al.
    • Journal Title

      Int J Cancer

      Volume: 133 Issue: 2 Pages: 505-13

    • DOI

      10.1002/ijc.28034

    • Peer Reviewed
    • Data Source
      KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-25860638
  • [Journal Article] mTOR inhibitors control erlotinib-resistance of EGFR mutant lung cancer cells triggered by HGF.2013

    • Author(s)
      Ishikawa D, Yano S, et al.
    • Journal Title

      PLoS ONE

      Volume: 8 Issue: 5 Pages: e62104-e62104

    • DOI

      10.1371/journal.pone.0062104

    • Peer Reviewed
    • Data Source
      KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23591141, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24591156, KAKENHI-PROJECT-25860638, KAKENHI-PROJECT-25860640
  • [Journal Article] Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.2013

    • Author(s)
      Zhao L, Yano S, et al.
    • Journal Title

      Cancer Sci

      Volume: 104 Issue: 12 Pages: 1640-6

    • DOI

      10.1111/cas.12301

    • NAID

      120005830610

    • Peer Reviewed
    • Data Source
      KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23501273, KAKENHI-PROJECT-23591632, KAKENHI-PROJECT-23591921, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-25860640
  • [Journal Article] Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer2012

    • Author(s)
      Nakagawa T
    • Journal Title

      Mol Cancer Ther.

      Volume: 11 Issue: 10 Pages: 2149-2157

    • DOI

      10.1158/1535-7163.mct-12-0195

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24659403
  • [Journal Article] Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer2012

    • Author(s)
      Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S
    • Journal Title

      J Thorac Oncol

      Volume: 7 Issue: 2 Pages: 272-80

    • DOI

      10.1097/jto.0b013e3182398e69

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209
  • [Journal Article] E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells2012

    • Author(s)
      Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Uenaka T, Yano S
    • Journal Title

      Clin Cancer Res

      Volume: 18 Issue: 6 Pages: 1663-71

    • DOI

      10.1158/1078-0432.ccr-11-1171

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24390210
  • [Journal Article] Dual inhibition of met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer2012

    • Author(s)
      Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano
    • Journal Title

      Am J Pathol

      Volume: 181 Issue: 3 Pages: 1034-1043

    • DOI

      10.1016/j.ajpath.2012.05.023

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390210, KAKENHI-PROJECT-24659403
  • [Journal Article] Ligand-triggered resistance to molecular targeted drugs in lung cancer : roles of HGF and EGFR ligands2012

    • Author(s)
      Yano S, Takeuchi S, Nakagawa T, Yamada T
    • Journal Title

      Cancer Sci

      Volume: (In press) Issue: 7 Pages: 1189-1194

    • DOI

      10.1111/j.1349-7006.2012.02279.x

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
  • [Journal Article] Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells2012

    • Author(s)
      Yamada, T.
    • Journal Title

      Clin. Cancer Res.

      Volume: 18 Issue: 13 Pages: 3592-3602

    • DOI

      10.1158/1078-0432.ccr-11-2972

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-23689043, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24659403
  • [Journal Article] Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR activating and gatekeeper mutations.2012

    • Author(s)
      Yamada T, Takeuchi S, et al.
    • Journal Title

      Oncogene.

      Volume: Epub ahead of print

    • NAID

      120004997024

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-23790903
  • [Journal Article] Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis2012

    • Author(s)
      Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.
    • Journal Title

      J Thorac Oncol

      Volume: (in press)

    • NAID

      40019570662

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256
  • [Journal Article] Hsp90 Inhibition Overcomes HGF Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis2012

    • Author(s)
      Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, and Yano S
    • Journal Title

      Journal of Thoracic Oncology

      Volume: Vol. 7: no.7 Issue: 7 Pages: 1078-1085

    • DOI

      10.1097/jto.0b013e3182519a2c

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24659403, KAKENHI-PLANNED-22112010
  • [Journal Article] Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer2011

    • Author(s)
      Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S
    • Journal Title

      Clin Cancer Res

      Volume: 17 Issue: 8 Pages: 2260-9

    • DOI

      10.1158/1078-0432.ccr-10-1993

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22240092, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
  • [Journal Article] The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer2011

    • Author(s)
      Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Takeuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
    • Journal Title

      Clin Cancer Res

      Volume: 17 Issue: 11 Pages: 3619-30

    • DOI

      10.1158/1078-0432.ccr-10-2475

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-ORGANIZER-22112001, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23591921, KAKENHI-PROJECT-23790902
  • [Journal Article] Genetically engineered humanized anti-ganglioside GM2 anti-body against multiple organ metastasis produced by GM2 expressing small cell lung cancer2011

    • Author(s)
      Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S.
    • Journal Title

      Cancer Sci

      Volume: 102 Issue: 12 Pages: 2157-63

    • DOI

      10.1111/j.1349-7006.2011.02093.x

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
  • [Journal Article] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort2011

    • Author(s)
      Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
    • Journal Title

      J Thorac Oncol

      Volume: 6 Issue: 12 Pages: 2011-7

    • DOI

      10.1097/jto.0b013e31823ab0dd

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-PROJECT-21591831, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
  • [Journal Article] E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor2011

    • Author(s)
      Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
    • Journal Title

      Mol Cancer Ther

      Volume: 10 Issue: 7 Pages: 1218-28

    • DOI

      10.1158/1535-7163.mct-10-0707

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
  • [Presentation] ALK融合遺伝子陽性肺がんにおけるSTAT3阻害薬の併用によるアポトーシス抵抗性の克服2021

    • Author(s)
      柳村尚寛、竹内伸司、新井祥子、福田康二、西山明宏、矢野聖二
    • Organizer
      第25回日本分子標的治療学会
    • Data Source
      KAKENHI-PROJECT-20K08516
  • [Presentation] 肺癌のアポトーシス抵抗性に起因する 分子標的薬耐性を克服する橋渡し研究2018

    • Author(s)
      竹内 伸司
    • Organizer
      第77回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-17K09649
  • [Presentation] ALK転座陽性肺癌においてEMTは独立した機構として関与する2018

    • Author(s)
      福田康二、竹内伸司、片山量平、南條成輝、山田忠明、鈴木健之、竹内健吾、西尾誠人、矢野聖二
    • Organizer
      第77回日本癌学会学術総会 2018
    • Data Source
      KAKENHI-PROJECT-18K07261
  • [Presentation] New therapeutic strategies for overcoming resistance to targeted drugs in lung cancer by HDAC inhibition2017

    • Author(s)
      竹内伸司
    • Organizer
      第76回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-17K09649
  • [Presentation] 医師主導治験による肺がんの新規分子標的治療の開発2017

    • Author(s)
      竹内伸司
    • Organizer
      第15回日本臨床腫瘍学会学術集会
    • Data Source
      KAKENHI-PROJECT-17K09649
  • [Presentation] HDAC inhibition overcomes crizotinib-resistance by inducing mesenchymal-epithelial reverting transition (MERT) via miR-200c up-regulation in EML4-ALK lung cancer cells.2016

    • Author(s)
      Koji Fukuda, Shigeki Nanjo, Shinji Takeuchi, Tadaaki Yamada, Ryohei Katayama, Kengo Takeuchi, Hiroshi Nishihara, Seiji Yano.
    • Organizer
      Tenth AACR-JCA Joint Conference
    • Place of Presentation
      Maui, Hawaii, USA
    • Year and Date
      2016-02-16
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-26860603
  • [Presentation] 分子標的薬に対する側副経路活性化による耐性メカニズム2012

    • Author(s)
      竹内伸司, 矢野聖二
    • Organizer
      日本がん分子標的治療学会第16回学術集会
    • Year and Date
      2012-06-28
    • Data Source
      KAKENHI-PROJECT-23790903
  • [Presentation] 分子標的薬に対する側副経路活性化による耐性メカニズム2012

    • Author(s)
      竹内伸司
    • Organizer
      日本がん分子標的治療学会第16回学術集会
    • Place of Presentation
      北九州市 西日本総合展示場
    • Data Source
      KAKENHI-PROJECT-23790903
  • [Presentation] Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer2011

    • Author(s)
      竹内 伸司
    • Organizer
      第70回日本癌学会学術総会
    • Place of Presentation
      名古屋国際会議場(愛知県)
    • Data Source
      KAKENHI-PROJECT-23790903
  • [Presentation] Met/VEGFR-2阻害剤E7050は変異型EGFR肺がんにおいてHGFによるEGFR-TKI耐性誘導を克服する2011

    • Author(s)
      竹内 伸司, Wang Wei, Li Qi, 山田 忠明, Donev Ivan, 小泉 瞳, 中村 隆弘, 松本 邦夫, 西岡 安彦, 曽根 三郎, 上仲 俊光, 矢野 聖二
    • Organizer
      第70回日本がん学会学術総会
    • Year and Date
      2011-10-03
    • Data Source
      KAKENHI-PROJECT-23790903
  • [Presentation] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. 2011 American Society of Clinical Oncology(ASCO)2011

    • Author(s)
      Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K
    • Organizer
      Annual Meeting
    • Place of Presentation
      McCormick Place(USA.)
    • Year and Date
      2011-06-04
    • Data Source
      KAKENHI-PROJECT-21390256
  • [Presentation] EGFR-TKI耐性とその克服

    • Author(s)
      竹内伸司、矢野聖二
    • Organizer
      第18回日本がん分子標的治療学会学術集会
    • Place of Presentation
      仙台
    • Year and Date
      2014-06-25 – 2014-06-27
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Presentation] BIM遺伝子多型に起因するEGFR-TKI耐性とHDAC阻害薬併用による耐性克服治療戦略

    • Author(s)
      竹内伸司, 中川学之, 長谷川好規, 矢野聖二
    • Organizer
      第54回日本肺癌学会総会
    • Place of Presentation
      東京
    • Invited
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Presentation] EGFR変異肺がんのEGFR-TKI耐性

    • Author(s)
      竹内伸司、矢野聖二
    • Organizer
      第54回日本呼吸器学会学術講演
    • Place of Presentation
      大阪
    • Year and Date
      2014-04-25 – 2014-04-27
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Presentation] BIM遺伝子多型に起因する分子標的薬耐性の克服

    • Author(s)
      竹内伸司, 中川学之, 矢野聖二
    • Organizer
      第11回日本臨床腫瘍学会学術集会
    • Place of Presentation
      仙台
    • Invited
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Presentation] Therapeutic strategies for overcoming resistance to EGFR-TKI and ALK-TKI by inhibition of Hsp90 or HADC

    • Author(s)
      竹内伸司、矢野聖二
    • Organizer
      第12回日本臨床腫瘍学会学術集会
    • Place of Presentation
      福岡
    • Year and Date
      2014-07-17 – 2014-07-19
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Presentation] EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition

    • Author(s)
      Takeuchi S, Nakagawa T, Yamada T, Yano S.
    • Organizer
      IASLC 15th World Conference on Lung Cancer
    • Place of Presentation
      シドニー
    • Invited
    • Data Source
      KAKENHI-PROJECT-25860640
  • [Presentation] BIM遺伝子多型によるEGFR-TKI耐性の治療法開発の現状

    • Author(s)
      竹内伸司、矢野聖二
    • Organizer
      第55回日本肺癌学会学術集会
    • Place of Presentation
      京都
    • Year and Date
      2014-11-14 – 2014-11-16
    • Data Source
      KAKENHI-PROJECT-25860640
  • []

  • 1.  YANO Seiji (30294672)
    # of Collaborated Projects: 2 results
    # of Collaborated Products: 18 results
  • 2.  Fukuda Koji (10722548)
    # of Collaborated Projects: 2 results
    # of Collaborated Products: 5 results
  • 3.  WANG Wei (80467117)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 5 results
  • 4.  YAMADA Tadaaki (00507048)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 10 results
  • 5.  菊地 利明
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 6.  阿部 貴志
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 7.  曽根 三郎
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 8.  西岡 安彦
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 9.  中村 隆弘
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results

URL: 

Are you sure that you want to link your ORCID iD to your KAKEN Researcher profile?
* This action can be performed only by the researcher himself/herself who is listed on the KAKEN Researcher’s page. Are you sure that this KAKEN Researcher’s page is your page?

この研究者とORCID iDの連携を行いますか?
※ この処理は、研究者本人だけが実行できます。

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi